Cargando…

TGF-β Serum Levels in Diabetic Retinopathy Patients and the Role of Anti-VEGF Therapy

Transforming growth factor β1 (TGFβ1) is a proinflammatory cytokine that has been implicated in the pathogenesis of diabetic retinopathy (DR), particularly in the late phase of disease. The aim of the present study was to validate serum TGFβ1 as a diagnostic and prognostic biomarker of DR stages. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Bonfiglio, Vincenza, Platania, Chiara Bianca Maria, Lazzara, Francesca, Conti, Federica, Pizzo, Corrado, Reibaldi, Michele, Russo, Andrea, Fallico, Matteo, Ortisi, Elina, Pignatelli, Francesco, Longo, Antonio, Avitabile, Teresio, Drago, Filippo, Bucolo, Claudio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7765505/
https://www.ncbi.nlm.nih.gov/pubmed/33334029
http://dx.doi.org/10.3390/ijms21249558
_version_ 1783628505846644736
author Bonfiglio, Vincenza
Platania, Chiara Bianca Maria
Lazzara, Francesca
Conti, Federica
Pizzo, Corrado
Reibaldi, Michele
Russo, Andrea
Fallico, Matteo
Ortisi, Elina
Pignatelli, Francesco
Longo, Antonio
Avitabile, Teresio
Drago, Filippo
Bucolo, Claudio
author_facet Bonfiglio, Vincenza
Platania, Chiara Bianca Maria
Lazzara, Francesca
Conti, Federica
Pizzo, Corrado
Reibaldi, Michele
Russo, Andrea
Fallico, Matteo
Ortisi, Elina
Pignatelli, Francesco
Longo, Antonio
Avitabile, Teresio
Drago, Filippo
Bucolo, Claudio
author_sort Bonfiglio, Vincenza
collection PubMed
description Transforming growth factor β1 (TGFβ1) is a proinflammatory cytokine that has been implicated in the pathogenesis of diabetic retinopathy (DR), particularly in the late phase of disease. The aim of the present study was to validate serum TGFβ1 as a diagnostic and prognostic biomarker of DR stages. Thirty-eight subjects were enrolled and, after diagnosis and evaluation of inclusion and exclusion criteria, were assigned to six groups: (1) healthy age-matched control, (2) diabetic without DR, (3) non-proliferative diabetic retinopathy (NPDR) naïve to treatment, (4) NPDR treated with intravitreal (IVT) aflibercept, (5) proliferative diabetic retinopathy (PDR) naïve to treatment and (6) PDR treated with IVT aflibercept. Serum levels of vascular endothelial growth factor A (VEGF-A), placental growth factor (PlGF) and TGFβ1 were measured by means of enzyme-linked immunosorbent assay (ELISA). Foveal macular thickness (FMT) in enrolled subjects was evaluated by means of structural-optical coherence tomography (S-OCT). VEGF-A serum levels decreased in NPDR and PDR patients treated with aflibercept, compared to naïve DR patients. PlGF serum levels were modulated only in aflibercept-treated NPDR patients. Particularly, TGFβ1 serum levels were predictive of disease progression from NPDR to PDR. A Multivariate ANOVA analysis (M-ANOVA) was also carried out to assess the effects of fixed factors on glycated hemoglobin (HbA1c) levels, TGFβ1, and diabetes duration. In conclusion, our data have strengthened the hypothesis that TGFβ1 would be a biomarker and pharmacological target of diabetic retinopathy.
format Online
Article
Text
id pubmed-7765505
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-77655052020-12-27 TGF-β Serum Levels in Diabetic Retinopathy Patients and the Role of Anti-VEGF Therapy Bonfiglio, Vincenza Platania, Chiara Bianca Maria Lazzara, Francesca Conti, Federica Pizzo, Corrado Reibaldi, Michele Russo, Andrea Fallico, Matteo Ortisi, Elina Pignatelli, Francesco Longo, Antonio Avitabile, Teresio Drago, Filippo Bucolo, Claudio Int J Mol Sci Article Transforming growth factor β1 (TGFβ1) is a proinflammatory cytokine that has been implicated in the pathogenesis of diabetic retinopathy (DR), particularly in the late phase of disease. The aim of the present study was to validate serum TGFβ1 as a diagnostic and prognostic biomarker of DR stages. Thirty-eight subjects were enrolled and, after diagnosis and evaluation of inclusion and exclusion criteria, were assigned to six groups: (1) healthy age-matched control, (2) diabetic without DR, (3) non-proliferative diabetic retinopathy (NPDR) naïve to treatment, (4) NPDR treated with intravitreal (IVT) aflibercept, (5) proliferative diabetic retinopathy (PDR) naïve to treatment and (6) PDR treated with IVT aflibercept. Serum levels of vascular endothelial growth factor A (VEGF-A), placental growth factor (PlGF) and TGFβ1 were measured by means of enzyme-linked immunosorbent assay (ELISA). Foveal macular thickness (FMT) in enrolled subjects was evaluated by means of structural-optical coherence tomography (S-OCT). VEGF-A serum levels decreased in NPDR and PDR patients treated with aflibercept, compared to naïve DR patients. PlGF serum levels were modulated only in aflibercept-treated NPDR patients. Particularly, TGFβ1 serum levels were predictive of disease progression from NPDR to PDR. A Multivariate ANOVA analysis (M-ANOVA) was also carried out to assess the effects of fixed factors on glycated hemoglobin (HbA1c) levels, TGFβ1, and diabetes duration. In conclusion, our data have strengthened the hypothesis that TGFβ1 would be a biomarker and pharmacological target of diabetic retinopathy. MDPI 2020-12-15 /pmc/articles/PMC7765505/ /pubmed/33334029 http://dx.doi.org/10.3390/ijms21249558 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Bonfiglio, Vincenza
Platania, Chiara Bianca Maria
Lazzara, Francesca
Conti, Federica
Pizzo, Corrado
Reibaldi, Michele
Russo, Andrea
Fallico, Matteo
Ortisi, Elina
Pignatelli, Francesco
Longo, Antonio
Avitabile, Teresio
Drago, Filippo
Bucolo, Claudio
TGF-β Serum Levels in Diabetic Retinopathy Patients and the Role of Anti-VEGF Therapy
title TGF-β Serum Levels in Diabetic Retinopathy Patients and the Role of Anti-VEGF Therapy
title_full TGF-β Serum Levels in Diabetic Retinopathy Patients and the Role of Anti-VEGF Therapy
title_fullStr TGF-β Serum Levels in Diabetic Retinopathy Patients and the Role of Anti-VEGF Therapy
title_full_unstemmed TGF-β Serum Levels in Diabetic Retinopathy Patients and the Role of Anti-VEGF Therapy
title_short TGF-β Serum Levels in Diabetic Retinopathy Patients and the Role of Anti-VEGF Therapy
title_sort tgf-β serum levels in diabetic retinopathy patients and the role of anti-vegf therapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7765505/
https://www.ncbi.nlm.nih.gov/pubmed/33334029
http://dx.doi.org/10.3390/ijms21249558
work_keys_str_mv AT bonfigliovincenza tgfbserumlevelsindiabeticretinopathypatientsandtheroleofantivegftherapy
AT plataniachiarabiancamaria tgfbserumlevelsindiabeticretinopathypatientsandtheroleofantivegftherapy
AT lazzarafrancesca tgfbserumlevelsindiabeticretinopathypatientsandtheroleofantivegftherapy
AT contifederica tgfbserumlevelsindiabeticretinopathypatientsandtheroleofantivegftherapy
AT pizzocorrado tgfbserumlevelsindiabeticretinopathypatientsandtheroleofantivegftherapy
AT reibaldimichele tgfbserumlevelsindiabeticretinopathypatientsandtheroleofantivegftherapy
AT russoandrea tgfbserumlevelsindiabeticretinopathypatientsandtheroleofantivegftherapy
AT fallicomatteo tgfbserumlevelsindiabeticretinopathypatientsandtheroleofantivegftherapy
AT ortisielina tgfbserumlevelsindiabeticretinopathypatientsandtheroleofantivegftherapy
AT pignatellifrancesco tgfbserumlevelsindiabeticretinopathypatientsandtheroleofantivegftherapy
AT longoantonio tgfbserumlevelsindiabeticretinopathypatientsandtheroleofantivegftherapy
AT avitabileteresio tgfbserumlevelsindiabeticretinopathypatientsandtheroleofantivegftherapy
AT dragofilippo tgfbserumlevelsindiabeticretinopathypatientsandtheroleofantivegftherapy
AT bucoloclaudio tgfbserumlevelsindiabeticretinopathypatientsandtheroleofantivegftherapy